- Advertisement -
The cardiovascular safety of interrupting beta-blocker could not be shown in comparison to continuation in patients with a history of myocardial infarction (MI) and there was no benefit to the patients’ quality of life, according to late-breaking research presented August 30 at ESC Congress…

